Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.
Muthiah VaduganathanRobert J MentzBrian L ClaggettZi Michael MiaoIan J KulacJonathan H WardAdrian F HernandezDavid A MorrowRandall C StarlingEric J VelazquezKristin M WilliamsonAkshay S DesaiShelley ZierothMartin LefkowitzJohn J V McMurrayEugene BraunwaldScott D SolomonPublished in: European heart journal (2023)
In pooled analyses of PARAGLIDE-HF and PARAGON-HF, sacubitril/valsartan reduced cardiovascular and renal events among patients with HF with mildly reduced or preserved ejection fraction. These data provide support for use of sacubitril/valsartan in patients with HF with mildly reduced or preserved ejection fraction, particularly among those with an LVEF below normal, regardless of care setting.